<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762615</url>
  </required_header>
  <id_info>
    <org_study_id>451/2018</org_study_id>
    <nct_id>NCT04762615</nct_id>
  </id_info>
  <brief_title>Impact of Underlying Renal Disease and Immunosuppressive Regimen on Ovarian Reserve in Renal Patients</brief_title>
  <official_title>Impact of the Immunosuppressive Treatment, X-ray Exposition and Renal Pathology on Ovarian Reserve in Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wroclaw Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aging, renal pathology (eg SLE, ADPKD), X-ray exposition and pharmacological treatments,&#xD;
      especially previous strong immunosuppression, may negatively influence the ovarian reserve in&#xD;
      childbearing age women. Anti-Müllerian hormone (AMH) is regarded as biomarker for ovarian&#xD;
      reserve.&#xD;
&#xD;
      Every female with renal disease regularly menstruating that met exclusion criteria could have&#xD;
      participated. The aim was to assess ovarian reserve in female patients with normal menstrual&#xD;
      cycle and kidney disease, including kidney transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 10, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>To compare AMH levels between three groups</measure>
    <time_frame>1 day</time_frame>
    <description>Serum AMH levels [ng/ml] measured using ELISA and compared between three groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential impact of X-ray exposition on ovarian reserve</measure>
    <time_frame>1 day</time_frame>
    <description>Analysis of the impact of X-ray exposition [mSv] on AMH serum level [ng/ml]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential impact of antiproliferative drugs on ovarian reserve</measure>
    <time_frame>1 day</time_frame>
    <description>Analysis of the impact of antiproliferative drugs on AMH serum level [ng/ml]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential impact of underlying kidney disease on ovarian reserve</measure>
    <time_frame>1 day</time_frame>
    <description>Analysis of the impact of underlying kidney disease (including SLE) on AMH serum level [ng/ml]</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">153</enrollment>
  <condition>Anti-Mullerian Hormone Deficiency</condition>
  <condition>Immunosuppression</condition>
  <condition>Ovarian Reserve</condition>
  <condition>X-rays; Effects</condition>
  <arm_group>
    <arm_group_label>Patients with renal pathology treated with immunosuppressive drugs</arm_group_label>
    <description>Female in reproductive age suffering from renal disease that is or was previously treated with immunosuppressive drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with renal pathology without treatment</arm_group_label>
    <description>Control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients after renal transplantation taking immunosuppressive drugs</arm_group_label>
    <description>Female in reproductive age after renal transplantation taking immunosuppressive drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>AMH level measurement</intervention_name>
    <description>AMH level measurement using ELISA test from blood samples</description>
    <arm_group_label>Patients after renal transplantation taking immunosuppressive drugs</arm_group_label>
    <arm_group_label>Patients with renal pathology treated with immunosuppressive drugs</arm_group_label>
    <arm_group_label>Patients with renal pathology without treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Regularly menstruating female patients suffering from renal pathology or after renal&#xD;
        transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Conscious written approval&#xD;
&#xD;
          -  Autoimmunological disorder with kidneys affection/ kidney transplant recipient-&#xD;
             Regular menstrual cycles&#xD;
&#xD;
          -  Age above 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Irregular menstrual cycles&#xD;
&#xD;
          -  Menopause&#xD;
&#xD;
          -  PCOS&#xD;
&#xD;
          -  Chemiotherapy or radiotherapy in the past&#xD;
&#xD;
          -  Surgical interventions within ovaries&#xD;
&#xD;
          -  Hypogonadotropic hypogonadism&#xD;
&#xD;
          -  Folliculoma&#xD;
&#xD;
          -  Age under 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Rasała, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wroclaw Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology and Transplantation Clinic University Hospital in Wrocław</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMH</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Ovarian Reserve</keyword>
  <keyword>X-Ray effects</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

